Ken Griffin Grifols Sa Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$6.28 - $9.38 $207,868 - $310,478	-33,100 Reduced 21.78%	118,900 $1.06 Million
Q2 2024 Aug 14, 2024	SELL	$6.27 - $7.7 $201,894 - $247,940	-32,200 Reduced 17.48%	152,000 $957,000
Q1 2024 May 15, 2024	BUY	$5.47 - $11.38 $848,944 - $1.77 Million	155,200 Added 535.17%	184,200 $1.23 Million
Q4 2023 Feb 14, 2024	BUY	$7.71 - $11.56 $201,231 - $301,716	26,100 Added 900.0%	29,000 $335,000
Q3 2023 Nov 14, 2023	SELL	$8.91 - $10.91 $201,366 - $246,566	-22,600 Reduced 88.63%	2,900 $26,000
Q2 2023 Aug 14, 2023	SELL	$7.14 - $9.29 $49,980 - $65,029	-7,000 Reduced 21.54%	25,500 $233,000
Q1 2023 May 15, 2023	SELL	$6.65 - $10.69 $198,835 - $319,631	-29,900 Reduced 47.92%	32,500 $239,000
Q4 2022 Feb 14, 2023	SELL	$5.96 - $8.53 $171,052 - $244,810	-28,700 Reduced 31.5%	62,400 $530,000
Q3 2022 Nov 14, 2022	BUY	$5.95 - $14.3 $542,045 - $1.3 Million	91,100 New	91,100 $561,000

162

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.91B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.